Jean Drouin, MD, is the founder and CEO of Clarify Health Solutions, which enables health systems, payers, and life sciences organizations to deliver more satisfying and efficient care through advanced analytics, machine learning, and digital care optimization solutions. Prior to Clarify, Jean was a Senior Partner at McKinsey & Company, where his roles included leading the global Healthcare IT and Digital Practice, setting up the UK and Australian Healthcare Practices, and serving as the founding Head of McKinsey Advanced Healthcare Analytics (MAHA). He also served as Head of Strategy for NHS London, which oversaw London’s $15B hospital and primary care system. In these roles, he served over 20 countries and 100 health systems and payers on engagements that generated over $1B in efficiency and quality improvements.

Jean is passionate about transforming healthcare delivery across the continuum of care. He has written and spoken extensively on value-based care, population health, new payment models and the role of big data and analytics in delivering better outcomes. Jean holds MD and MBA degrees from Stanford and an AB in Molecular Biology from Princeton. He is the former Vice Chair of Lester B. Pearson United World College of the Pacific.

Calum MacRae, MD, PhD, is the Vice Chair for Translational Innovation in the Department of Medicine at Brigham and Women’s Hospital in Boston, an Associate Professor of Medicine at Harvard Medical School, a Principal Faculty Member at the Harvard Stem Cell Institute, and an Associate Member at the Broad Institute of Harvard and MIT. He was previously Chief of the Cardiovascular Medicine Division at Brigham and Women’s Hospital and Cardiology Fellowship Program Director at Massachusetts General Hospital.

Dr. MacRae works on the human genetics of disease, developmental contributions to health and disease, and on novel approaches to drug discovery He has a longstanding interest in the incorporation of genomics and novel large-scale datasets into clinical practice, systematic approaches to the discovery of new translatable digital biomarkers, and the role of disruptive innovation in refashioning the translational interface.